Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
Moderna will morph into a company that boasts “one of the biggest pipelines in the industry” in five years’ time, with 100 or 150 products expected to be in development, a big jump from the current 46, CEO Stephane Bancel…
To read the full story
Related Article
- Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
- Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
BUSINESS
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
- Medipal, JCR Launch Global PI/II of MPS IIIB Therapy
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…